Letrozole 2.5 - Unique Pharma

Letrozole, a potent third-generation aromatase inhibitor, was approved by the FDA in 1997 and is widely marketed under the brand name Femara. It is primarily prescribed for estrogen receptor-positive breast cancer in postmenopausal women, often following tamoxifen therapy. Letrozole effectively reduces estrogen levels by up to 78%, minimizing risks of gynecomastia and water retention in steroid users. Despite its effectiveness, it may lead to side effects such as joint pain, fatigue, and potential cardiovascular risks, especially during prolonged use .

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Letrozole 2.5 by Unique Pharma, consult with your doctor or healthcare professional.